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Abstract  
Background: Pharmacological interventions for Lewy body dementia (LBD), especially for 
its non-cognitive symptoms, are limited in their efficacy and tolerability. Clinicians are often 
uncertain about non-pharmacological interventions and their efficacy in managing cognitive 
and non-cognitive symptoms of LBD. Therefore, we aimed to systematically review existing 
literature on non-pharmacological interventions for people with LBD. 
Methods: We carried out a systematic search using six databases. All human studies 
examining impact of any non-pharmacological intervention on LBD were assessed for 
cognitive, physical, psychiatric, and quality-of-life outcomes. Study quality was assessed by 
effective public health practice project quality assessment tool for quantitative studies and the 
CARE criteria checklist. 
Results: Prevailing evidence supporting the efficacy of non-pharmacological interventions is 
weak. We screened 1647 papers. Fifteen studies (N=61) including 11 case reports were found 
eligible for this systematic review.  Interventions and reported outcomes were heterogeneous. 
Deep brain stimulation of the nucleus basalis of Meynert reportedly confer cognitive benefit. 
Electroconvulsive therapy and repetitive transcranial magnetic stimulation have been 
reported to ameliorate depressive symptoms. Transcranial direct current stimulation was 
observed to improve attention. Exercise-based interventions reportedly improve various 
clinically important outcomes. Spaced retrieval memory training and environmental 
intervention for ‘mirror sign’ have also been reported. 
Conclusions: Several non-pharmacological interventions have been studied in LBD. 
Although evidence supporting their efficacy is not robust, prevailing preliminary evidence, 
and limitations of available pharmacological interventions indicate the need to consider 
appropriate non-pharmacological interventions, while planning comprehensive care of LBD 
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patients. Larger trials evaluating the efficacy of non-pharmacological interventions for LBD 
are needed. 
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Introduction 
Lewy body dementia (LBD) is the second most prevalent form of neurodegenerative 
dementia. The term LBD encompasses two overlapping clinical syndromes, dementia with 
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), which are conservatively 
estimated to contribute to 4.2-7.5% (Vann Jones and O'Brien, 2014) and 3.1-4.1% (Aarsland 
et al., 2005) of all dementia, respectively. Notably, it has been reported that caregivers of 
people with DLB experience greater distress because of behavioral symptoms than in 
Alzheimer’s dementia (AD) (Svendsboe et al., 2016). Compared with other forms of 
dementia, LBD patients display an increased risk of mortality (Oesterhus et al., 2014), earlier 
nursing home admissions (Rongve et al., 2014), raised risk of falling (Komatsu, 2013), and 
reduced quality of life (Figari-Jordan et al., 2012). Therefore, whilst LBD is not as common 
as AD, its relative burden on service users, their caregivers, and society is substantial. 
Although much work has gone into the development of pharmacological therapies for 
LBD (Stinton et al., 2015), as yet there are no disease-modifying treatments available. 
Management of neuropsychiatric symptoms in people with LBD is challenging. Recurrent 
well-formed visual hallucinations and delusional beliefs are common in LBD, but 
parkinsonism and severe neuroleptic sensitivity mandate minimizing use of antipsychotics. 
Limitations of available pharmacological interventions for LBD, especially for non-cognitive 
symptoms, include lack of high quality evidence for their efficacy (Stinton et al., 2015), poor 
tolerability, and the potential risks of serious adverse effects. Hence, non-pharmacological 
interventions often play an important role in clinical management of people with LBD. 
Systematic research evaluating non-pharmacological interventions for LBD is sparse, and 
pertinent prevailing evidence is not readily available to interested clinicians. A recent 
systematic review has reported the impact of exercise therapy in LBD (Inskip et al., 2016), 
but it did not include other non-pharmacological interventions for LBD, such as transcranial 
6 
 
direct current stimulation (tDCS) (Elder et al., 2016), deep brain stimulation (DBS) (Barnikol 
et al., 2010; Freund et al., 2009), electroconvulsive therapy (ECT) (Takahashi et al., 2009), 
or repetitive transcranial magnetic stimulation (rTMS). Updated knowledge regarding these 
non-pharmacological interventions may help clinicians to formulate comprehensive care 
plans for people with LBD. Therefore, we aimed to carry out the first comprehensive 
systematic review of the efficacy of all reported non-pharmacological interventions for 
cognitive and non-cognitive symptoms of LBD.  
 
Methods 
Study design  
The protocol of this systematic review has been registered (PROSPERO protocol registration 
number: CRD42016049642), and is available online (www.crd.york.ac.uk/PROSPERO/). 
Inclusion criteria  
We employed broad inclusion criteria, and considered all eligible original studies regardless 
of their quality or design. (i) Population: Studies investigating individuals of any gender, age 
and ethnicity with a clinical diagnosis of LBD were considered. Therefore, studies focusing 
on treatment of individuals with Parkinson’s disease (PD) without dementia were not 
included. Additionally, studies which assessed an intervention in any form of dementia 
without separately reporting outcomes for LBD were not included. These studies were not 
included because of prior publication of comprehensive systematic reviews on non-
pharmacological interventions for people with PD (Hindle et al., 2013) and for behavioral 
symptoms of dementia (Abraha et al., 2017). Animal studies were not included. (ii) 
Interventions: Studies investigating any non-pharmacological intervention for LBD were 
included. These included: physical and occupational therapy, exercise, social interaction, 
cognitive therapy, mindfulness, behavioral therapy, bright light therapy, tDCS, deep brain 
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stimulation, ECT, rTMS, music therapy, and other potential alternative therapies. These 
interventions were included regardless of whether they were acute or long-term. (iii) 
Comparison: No restrictions were applied. (iv) Outcomes: No restrictions were applied in 
order to avoid excluding relevant studies. 
Search strategy  
A systematic search was performed in December 2016 using the following six databases: 
MEDLINE, PsycINFO, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, 
and OpenGrey. The search strategy was comprised of both ‘Population’ AND ‘Intervention’ 
terms. These terms were searched in titles and abstracts of papers and grey literature. 
‘Comparison’ and ‘Outcome’ terms were not used to ensure better search sensitivity.  The 
population search terms used were: (‘Parkinson*’ AND ‘dementia’) OR (‘Lewy’ AND 
‘dementia’).The intervention search terms used were: ‘exercise’ OR ‘physical therapy’ OR 
‘occupational therapy’ OR ‘social interaction’ OR ‘cognitive therapy’ OR ‘cognitive 
treatment’ OR ‘mindfulness’ OR ‘behavio?ral therapy’ OR ‘behavio?ral treatment’ OR 
‘bright light therapy’ OR ‘pet therapy’ OR ‘education*’ OR ‘music therapy’ OR ‘transcranial 
direct current stimulation’ OR ‘transcranial magnetic stimulation’ OR ‘deep brain stimulation’ 
OR electroconvulsive therapy’ OR ‘alternative therapy’ OR ‘non-pharmacological treatment’ 
OR non-pharmacological intervention’ OR ‘non-pharmacological approach’. We did not 
specify any language limits, and we included non-English articles in the search strategy. 
However, only one non-English paper was identified as relevant (Fujiwara et al., 2004).  
Study selection  
Screening followed several steps, the first of which was merging of duplicates using 
Mendeley Desktop 1.17.1 (Mendeley Ltd., London, UK). After this, papers with titles 
unrelated to dementia or PD were excluded, with subsequent exclusion of papers with 
abstracts which did not mention the use of any non-pharmacological intervention. This was 
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followed by exclusion of full text articles found to be ineligible, more specifically this 
involved excluding: articles focused on interventions for PD excluding or not controlling for 
PDD, articles focused on interventions for dementia excluding or not controlling for LBD, 
and articles providing insufficient details on their methods or outcomes. Ultimately, full text 
articles assessed to be eligible by the authors were reviewed, with resulting suitable articles 
included in the systematic review. 
Quality assessment  
Quality and potential likelihood of bias of eligible studies were assessed using the CARE 
criteria checklist (Gagnier et al., 2013) for case reports, and the Effective Public Health 
Practice Project (EPHPP) Quality Assessment Tool for Quantitative Studies (Thomas et al., 
2004) for trials. We did not find any eligible qualitative studies. Studies were second-marked 
by independent raters, with any scoring inconsistencies resolved through discussion.  
Data extraction  
For each study deemed eligible for inclusion, extraction of the following data categories took 
place. (i) Study design: Studies were either considered experimental (randomized control 
trials (RCT) and non-randomized control trials (NRCT), uncontrolled trials (UCT)), or 
observational (case reports, case series, cross-sectional, case-control, prospective or 
retrospective cohort). (ii) Intervention or exposure: Method, frequency, intensity and duration 
of each study’s non-pharmacological intervention were assessed. (iii) Cohort: Cohort was 
classified by any combination of diagnosis, age, gender, living or not living in the community, 
Unified Parkinson’s Disease Rating Scale (UPDRS) (Martinez-Martin et al., 1994) or other 
mobility scores, Mini-mental State Examination (MMSE) (Folstein et al., 1975) or other 
cognitive test scores, and medications being taken. (iv) Outcome: Outcomes were classified 
according to the measurement test or tool used, mean differences between groups, effect sizes, 
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confidence intervals (CI), and statistical difference between groups, if such data were 
available.  
Data synthesis  
Studies were initially grouped on the basis of types of employed non-pharmacological 
interventions. They were regrouped on the basis of outcomes relevant to cognitive, 
neuropsychiatric, and motor symptoms of LBD. We assessed the levels of evidence using 
guidelines from the Oxford center for Evidence-Based Medicine (OCEBM-Levels-of-
Evidence-Working-Group, 2011). 
 
Results 
Identified studies  
Figure 1 outlines the study selection process in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) format. A joint search of EMBASE, MEDLINE, and 
PsycINFO unveiled 2171 papers. A further 1075 papers were found on CINAHL, whilst 323 
were found on Cochrane Central Register of Controlled Trials, and 26 were found on 
OpenGrey. The 15 eligible articles included a single-blind randomized controlled trial (RCT) 
that included only four people with PDD (Telenius et al., 2015), three uncontrolled trials 
(UCT) (Elder et al., 2016; Rochester et al., 2009; Takahashi et al., 2009), and eleven case 
reports (Barnikol et al., 2010; Ciro et al., 2013; Dawley, 2015; Freund et al., 2009; Fujiwara 
et al., 2004; Gil-Ruiz et al., 2013; Hayden and Camp, 1995; Kim et al., 2017; Loher et al., 
2002; Rasmussen et al., 2003; Tabak et al., 2013).  
Quality of included studies  
When assessing quality of experimental trials, all four identified studies received weak or 
moderate global rating on the EPHPP quality assessment tool (see supplemental digital 
content (SDC)-1 attached to the electronic version of this paper at 
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http://journals.cambridge.org/ipg). Failure to control for confounders was a common 
limitation. In the case of exercise interventions, blinding is difficult to achieve because of the 
nature of intervention. Case report quality also varied, ranging from 11/28 (Barnikol et al., 
2010) to 23/28 (Dawley, 2015) on the 2016 CARE criteria checklist (See SDC-2). Despite 
five case reports scoring 20/28 or greater, one should note that case reports are inherently 
susceptible to selection, detection, and reporting biases. This may skew perception of efficacy, 
especially when outcomes from several case reports are assessed as a group. 
Participant characteristics  
In total, 61 individuals with LBD were included in this review. There were 31 with PDD, 22 
with DLB, and 8 individuals, who are only described as having LBD. Table 1 presents further 
details of the individuals with LBD. Notably, the same individual has been assessed in two 
case reports for different outcomes following the same intervention (Barnikol et al., 2010; 
Freund et al., 2009) and thus has been assessed as a single person. Data on four PDD patients 
were obtained from a systematic review (Inskip et al., 2016) due to primary data being 
reported as an average across 170 dementia patients (Telenius et al., 2015). Participants were 
predominantly men (57.4%), and mean age was 70.3 years (95% CI 64.8-75.8). Scores 
indicating baseline cognitive function were reported for various tests including MMSE (n=44, 
mean=2.0, SD=13.8), and Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) 
(n=14, mean=19.9, SD=13.0). Years since dementia onset was reported only in six studies 
(n=22, mean=2.4, SD=4.3). Five studies have reported years since onset of PD (n=18, 
mean=7.8, SD=10.1). In most studies, individuals took neuropsychiatric medications during 
the intervention period. However, two studies did not report whether participants were also 
taking medication (Rochester et al., 2009; Takahashi et al., 2009). 
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Efficacy of ECT  
The highest level of evidence for benefits of ECT in treating depressive symptoms of LBD 
comes from the uncontrolled study in which the Hamilton Depression Rating Scale (HDRS) 
score (Hamilton, 1960) was observed to decrease significantly (p<0.005) from 38.0 (SD=5.8) 
to 15.0 (SD=9.6) (Takahashi et al., 2009) (Table 2). The evidence for improvement of 
psychotic symptoms in people with LBD following ECT is limited, with one case series 
indicating reduction in hallucinations following ECT in two out of seven individuals with 
LBD (Rasmussen et al., 2003) and another case report observing reduction in hallucinations 
and paranoid delusions following ECT (Fujiwara et al., 2004) (See SDC-3). 
Efficacy of DBS  
A case report examining the effects of bilateral stimulation of the subthalamic nucleus (STN) 
and the nucleus basalis of Meynert (NBM) in PDD has supported the efficacy of DBS in 
treating cognitive deterioration (Freund et al., 2009) (Table 3). Improvements in Auditory 
Verbal Learning and Memory Test (AVLT) (Lezak et al., 2012) and other tests of cognitive 
functions have been reported (Table 3). A case report has reported minor improvement in 
Beck Depression Inventory (BDI-II) scores in a PDD patient following DBS of both STN and 
NBM (Freund et al., 2009). Whilst the efficacy of DBS for motor symptoms of PD is well 
established (Baizabal-Carvallo and Alonso-Juarez, 2016), there is less evidence for its effect 
in LBD specifically. A case series has reported motor benefits of DBS in LBD. 
Improvements in UPDRS motor scores were observed following bilateral STN DBS. 
However, motor improvements lasted only 2-3 years in four individuals with LBD (Kim et al., 
2017) (See SDC-4). 
Efficacy of rTMS  
An uncontrolled study evaluating the efficacy of rTMS to treat depressive symptoms in 
people with LBD has reported statistically significant reduction of HDRS scores (p<0.005) 
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following rTMS (Takahashi et al., 2009). The study has reported reduction of HDRS scores 
from 24.0 (SD=8.0) before the intervention to 11.0 (SD=5.9) after the intervention (Table 2). 
The efficacy of rTMS in treating other symptoms of LBD has not been evaluated 
systematically so far (See SDC-3). 
Efficacy of tDCS  
Evidence supporting efficacy of tDCS in ameliorating cognitive symptoms of LBD comes 
from an uncontrolled study in which 13 patients underwent stimulation of the left dorsolateral 
prefrontal cortex (Table 2). Performance of attention and visuoperceptual tasks was assessed 
before and after treatment, with percentage of correct answers and the mean reaction time for 
digit vigilance being seen to improve significantly (Table 2). However, changes in 
visuoperceptual task performance were not statistically significant (Elder et al., 2016). There 
has not been any study evaluating the efficacy of tDCS in managing non-cognitive symptoms 
of LBD (See SDC-3). 
Efficacy of physical exercise  
Physical exercise is the most studied psychosocial intervention in people with LBD. Evidence 
supporting the benefits of exercise on cognition in PDD comes from a case report presenting 
an eight-week program of stationary cycling. Improvements in executive functions were 
observed using MoCA and PD cognitive rating scale (Pagonabarraga et al., 2008). Exercise 
has been reported to increase mood and cognition (UPDRS part I) scores, and to reduce the 
time needed to complete color trails tests 1 and 2 (Messinis et al., 2011; Tabak et al., 2013) 
(Table 4). Of all non-pharmacological interventions for motor symptoms of LBD, exercise-
based interventions have the best available evidence supporting their efficacy. However, 
there has not been any trial exclusively recruiting people with LBD. A subset of PDD patients 
(n=4) in a RCT, where participants undergoing the high intensity functional exercises 
program (Littbrand et al., 2006) were compared with a light activity control, has provided 
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evidence for minor improvements in sit-to-stand function and habitual and maximal gait 
speed. Exercise may improve balance, measured by the Berg balance scale (Inskip et al., 
2016; Telenius et al., 2015) (See SDC-5). 
Other non-pharmacological interventions  
Spaced retrieval memory training has been attempted as an intervention in PDD (n=2), 
though only one participant was able to successfully complete motor and motor-verbal tasks 
at final recall testing (Hayden and Camp, 1995). Additionally, one case report observed 
amelioration of ‘mirror sign’ associated with LBD, following an environmental intervention 
(Gil-Ruiz et al., 2013). 
 
Discussion 
This systematic review is the first to comprehensively assess the efficacy of all 
reported non-pharmacological interventions in people with LBD, and it conformed to the 
PRISMA guidelines (Moher et al., 2009). Table 5 summarizes the best available evidence for 
the efficacy of non-pharmacological interventions in treating various symptoms of LBD. The 
best available evidence supporting efficacy of non-pharmacological interventions is not 
robust. Currently available studies are small in scale. They often lack appropriate controls, 
and most of them have not accounted for potential confounding factors. Because of the lack 
of data homogeneity, secondary to the varying interventions assessed, and low quality of 
available literature, we could not perform meta-analysis. However, this preliminary evidence, 
together with the limitations of currently available pharmacological interventions, indicate 
the need to consider potential non-pharmacological interventions while planning 
comprehensive clinical care of people with LBD, and to plan pertinent research in future.  
ECT is a non-pharmacological intervention that is readily available to many specialist 
psychiatric services treating people with LBD. Whilst ECT has been associated with transient 
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cognitive deficits in late-life depression, current evidence does not suggest long-term 
deleterious effects on cognition (Kumar et al., 2016). Furthermore, a systematic review of the 
effects of ECT in PD and depression found depression improving in 93.1% of patients, with 
94% remaining free from cognitive decline (Borisovskaya et al., 2016). Extrapolating this 
evidence may support the safety of ECT in people with LBD. However, only one of three 
studies assessing ECT in LBD reported significant improvement in depression, and the study 
did not report post-ECT cognitive test results (Takahashi et al., 2009). Though there has not 
been any study suggesting hastening of cognitive decline by ECT in LBD, there is a need for 
studies investigating long-term cognitive effects of ECT in people with LBD. Considering the 
efficacy of ECT in ameliorating severe depression and psychosis in older people with PD, 
ECT may be a potential treatment option for people with LBD, especially those who do not 
tolerate pharmacological interventions, with severe neuropsychiatric symptoms leading to 
active risks to self and others. The need for large robust trials evaluating the efficacy of ECT 
in treating such neuropsychiatric symptoms in LBD cannot be overemphasized.  
Similarly, significant improvement of depressive symptoms in people with DLB 
following rTMS has been reported, but the report did not mention their post-rTMS cognitive 
functioning (Takahashi et al., 2009). A recent meta-analysis has found rTMS to be superior 
to sham-rTMS in reducing depressive symptoms in people with PD, with antidepressant 
effects similar to that of selective serotonin reuptake inhibitors, and concurrent improvement 
in motor function (Xie et al., 2015). Another systematic review has found rTMS to have no 
significant impact on cognition (Lage et al., 2016). There has not been any double blind RCT 
evaluating the efficacy and safety of rTMS in reducing depressive symptoms in people with 
LBD, despite the need for such a trial. Whilst attentional improvements have been reported in 
people with LBD following tDCS, it is important to note that removal of outliers could have 
influenced the results (Elder et al., 2016). Anodal tDCS over the prefrontal cortex has 
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previously shown efficacy in improving executive functions in people with PD (Boggio et al., 
2006; Cappon et al., 2016; Pereira et al., 2013). Hence, the efficacy of tDCS on executive 
functions of people with LBD requires further systematic investigation. 
DBS involves an invasive neurosurgical procedure, and is therefore not feasible in 
many psychiatric settings treating people with LBD. Whilst DBS is used clinically for 
medication-refractory motor symptoms in PD, PDD is often considered a contraindication in 
DBS, partially due to the risk of postsurgical cognitive decline, particularly upon STN 
stimulation (Massano and Garrett, 2012). However, this systematic review identified four 
case reports reporting benefits of DBS in PDD. Freund et al. suggest that cognitive 
improvements observed in their patient were due to the effects of stimulating residual 
cholinergic projections and cell bodies in NBM (Freund et al., 2009). Whilst it is not clear if 
NBM DBS alters progression of LBD, preclinical studies have suggested possible disease 
modifying mechanisms such as increased secretion of nerve growth factor (Hotta et al., 2009) 
and enhanced neurogenesis (Jeong et al., 2014). We came across two ongoing RCTs 
(Foltynie, 2017; Godefroy et al., 2017) evaluating the efficacy of NBM DBS to treat 
cognitive symptoms of DLB. Results of these trials have not been published so far. Due to the 
nature of the intervention, difficulties in obtaining informed consent, and the likelihood of 
end-stage complications, it is important to consider on an individual basis whether DBS can 
be justified as a treatment option, particularly for those with moderate or severe LBD.  
Several physical, cognitive, and quality of life outcome improvements have been 
reported in people with LBD receiving exercise-based interventions. Post-intervention 
increase in gait speed of 0.2 m/s or more has been reported in four studies, and this exceeds 
reported moderately clinically significant change of 0.14 m/s in PD cohorts (Hass et al., 
2014). A large clinically important effect in UPDRS section II scores following stationary 
cycling intervention has been reported (Tabak et al., 2013). A 50m improvement in six-
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minute walk test indicates moderately clinically significant change in geriatric populations, 
and an 82m improvement has been reported in a DLB patient following an exercise-based 
intervention (Dawley, 2015; Inskip et al., 2016; Steffen and Seney, 2008). There is currently 
level 4 evidence to support the efficacy of exercise-based interventions to improve cognition, 
activities of daily living, motor symptoms, and depressive symptoms in people with LBD. 
Although the prevailing evidence is not robust, practicability, potential benefits, and minimal 
risk for serious adverse effects indicate the need to include exercise-based interventions in the 
comprehensive clinical care of people with LBD. The importance of further research on this 
topic cannot be overemphasized. Efficacy of other psychosocial interventions including 
psychoeducation and carer-based interventions has not been systematically investigated in 
LBD, and there is urgent need to design pertinent trials. 
Studies evaluating non-pharmacological interventions for LBD are few, and they do 
not provide high-level evidence. Apart from the evidence supporting the use of 
acetylcholinesterase inhibitors for the management of cognitive symptoms of LBD, high-
level evidence for the efficacy of available pharmacological interventions in people with 
LBD are also sparse (Stinton et al., 2015). Considering the magnitude of burden on people 
with LBD, and on their caregivers, there is a clinical need to formulate individualized 
comprehensive care plans including both pharmacological and non-pharmacological 
interventions. There is an urgent need to expand pertinent evidence base. Among the 122 full-
text articles that were identified, 86 (70.5%) were considered ineligible because of their 
exclusion of or failure to control for PDD in PD cohorts, or for LBD in dementia cohorts. It is 
high time to reconsider the eligibility criteria excluding people with LBD, and to design trials 
specifically investigating people with LBD. Non-pharmacological intervention trials deal 
with unique methodological challenges (Boutron et al., 2008). Special attention should be 
given to standardizing different components of the intervention, tailoring the intervention for 
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the needs of individual participants, describing the expertise of intervention providers, and 
the choice of an appropriate control group. Non-pharmacological interventions that have 
shown promise in the management of PD may be investigated in people with LBD (Hindle et 
al., 2013). Ultimately, robust complex intervention trials evaluating the efficacy of combined 
pharmacological and non-pharmacological interventions are needed to develop 
comprehensive clinical guidelines for the management of people with LBD. 
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Figure legend 
Figure 1. PRISMA flow diagram of the systematic review  
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Table 1. Characteristics of individuals with LBD included in this systematic review 
Citation Number of 
participants 
Age 
Mean (SD) 
Gender Diagnosis MMSE / other 
COG scores 
Mean (SD) 
UPDRS 
Mean (SD) 
Prescribed 
neuropsychiatric drugs 
Residential 
Status 
Hayden et al., 1995  2 72  
(11.3) 
2 M PDD 23.5 (3.5);  
DRS: 110.5 
(2.1) 
NR Non-specified medication 
for Parkinson's 
Community 
Loher et al., 2002  1 75 M PDD 22 Part III 
31(ON), 
52(OFF) 
Carbidopa/levodopa; 
paroxetine 
Community 
Rasmussen et al., 2003  7 73.6 
(10.6) 
2 M, 5 F LBD 18.3 (7.4) NR Various antidepressants; 
antipsychotics; mood 
stabilisers; donepezil in 5; 
Carbidopa/levodopa in 2. 
Case 1: 
Community 
Fujiwara et al., 2004  1 20 F DLB 22 NR Carbidopa/levodopa; 
cabergoline; quetiapine 
Community 
Takahashi et al., 2009 
(ECT)  
8 71.6 
 (7.3) 
1 M, 7 F 3 possible 
DLB,  
5 probable 
DLB 
NR NR At least 2 antidepressants; 
lithium carbonate; sodium 
Valproate (withdrawn 
prior to ECT) 
NR 
Takahashi et al., 2009 
(rTMS)  
6 61.9  
(9.2) 
3 M, 3 F 5 suspected 
DLB,  
1 probable 
DLB 
NR NR NR NR 
Freund et al., 2009; 
Barnikol et al., 2010  
1 71 M PDD CDT: 4; 
AVLTsum: 12
 
NR Dopaminergic medication NR 
Rochester et al., 2009  9 74.9 
 (6.5) 
9 M PDD 22 (3.0) Part III, 44 
(7.2) 
NR Community 
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Data given as mean or individual values where appropriate. Figures rounded to one decimal place. Note that demographic data from Telenius et 
al. 2015 was unavailable for the four PDD participants and thus was acquired from a systematic review which had obtained results directly from 
the authors (Inskip et al., 2016). AVLT–Auditory Verbal Learning and Memory Test; CDT–Clock Drawing Task; COG- cognitive assessment; 
DLB–Dementia with Lewy bodies; DRS–Mattis Dementia Rating Scale; ECT–Electroconvulsive therapy; F- Women; M- Men; MCI–Mild 
cognitive impairment; MMSE–Mini-mental state Examination score; MoCA–Montreal Cognitive Assessment; NR–Not Reported; PDD–
Parkinson’s Disease Dementia; rTMS–repetitive transcranial magnetic stimulation; UPDRS=Unified Parkinson’s disease rating scale (Part I–
Mood and cognition, Part II–Activities of daily living, Part III–Motor).  
Gil-Ruiz et al., 2013  1 85 F Probable 
LBD 
19 NR Donepezil; escitalopram Nursing home 
Ciro et al., 2013  1 73 F DLB 12 NR Citalopram; 
Rivastigmine; Rasagiline 
Community 
Tabak et al., 2013  1 61 M PDD MoCA: 17 Part I: 11;  
Part II: 15 
Carbidopa/levodopa Community 
Dawley, 2015  1 57 M DLB NR NR Carbidopa/levodopa; 
antidepressant; 
antipsychotic 
Community 
Telenius et al., 2015  4 84.0  
(10.0) 
1 M, 3 F PDD 16 (7.1) NR NR Nursing home 
Elder et al., 2016  5 65.0  
(7.7) 
3 M, 2 F DLB 20.6 (3.1); 
MoCA: 17.6 
(3.7) 
Part III 12.8 
(5.6) 
1 on cholinesterase 
inhibitors; all on anti-
Parkinsonian medication 
NR 
Elder et al., 2016  8 64.6  
(8.2) 
7 M, 1 F PDD 22.0 (2.6); 
MoCA:  
19.4 (2.5) 
Part III 28.5 
(9.4) 
3 on antidepressants; all 
on anti-Parkinsonian 
medication 
NR 
Kim et al., 2016  5 66.0 
(1.9) 
3 M, 1 F PDD 21.6 (3.8) Part III 19.4 
(4.1) (ON), 
25.7 (11.9) 
(OFF) 
None on cholinesterase 
inhibitors; all on levodopa 
Community 
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Table 2. Reported outcomes following electroconvulsive therapy, repetitive transcranial 
magnetic stimulation and transcranial direct current stimulation in people with Lewy body 
dementia (n=35) 
Citation Measure/Feature Baseline Outcome 
ECT 
Rasmussen et 
al., 2003  
Case 1 MMSE (/30) 24 23-28 
 HDRS NR (‟severe 
depression”) 
6-8 
Visual hallucinations Intense and persistent Reduction in intensity 
Case 2 MMSE (/30) 19 23 
HDRS 33 8 
Case 3 MMSE (/30) 4 4 
Visual hallucinations Present Markedly reduced for 2 
weeks then recurred 
Case 4 MMSE (/30) NR  6-19 
HDRS NR (‟severe 
depression”) 
18-27 
Case 5 MMSE (/30) 28 21 
HDRS 17 17 (mood reportedly 
improved) 
Case 6 Depression Present Temporarily improved 
Delusion Prominent Temporarily reduced 
Case 7 Depression (/30) Present Acute improvement 
Fujiwara et 
al., 2004  
Clinical features Insomnia, mild 
depression, 
hallucinations and 
delusions 
Alleviation of depressed 
mood, hallucinations 
and delusions 
Takahashi et 
al., 2009  
HDRS 38.0 (5.8) 15.0 (9.6) 
rTMS 
Takahashi et 
al., 2009  
HDRS 24.0 (8.0) 11.0 (5.9) 
tDCS 
Elder et al.,  
2016  
Choice Reaction Time - Correct 
Answers (%) 
71.8 (28.3) 87.7 (20.9) 
Digit Vigilance - Mean 
Reaction Time (ms) 
632.9 582.9 
Figures rounded to one decimal place. ECT–Electroconvulsive therapy; HDRS- Hamilton 
Depression Rating Scale; MMSE–Mini-Mental State Examination; NR–Not reported; rTMS–
Repetitive transcranial magnetic stimulation; tDCS–Transcranial direct current stimulation. 
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Table 3. Outcomes following deep brain stimulation in people with Lewy body dementia at time points relative to electrode implantation (n=7) 
Citation Time of recording ADL  
(UPDRS Part II) 
Motor  
(UPDRS Part III) 
MMSE 
Off On Off On  
Loher et al., 2002  Preoperative 32 20 52 31 22 
3 months postoperative 26 18 40 21 17 
1 year postoperative 34 21 43 33 8 
Kim et al., 2016  Preoperative NR NR 49.9  
(19.1) 
36.4 
(37.7) 
21.6  
(3.8) 
1 year postoperative NR NR 25.7  
(11.9) 
19.38 
(4.1)A 
23.5  
(2.4)B 
Citation Time of recording AVLTsum, 
(No. of 
words) 
CDT 
(points) 
TMT-A 
(minutes: 
seconds) 
Vflsum 
(No. of 
words) 
BDI-II 
(points) 
Freund et al., 2009; 
Barnikol et al., 2010  
Preoperative 12 4 05:24 23 26 
Bilateral stimulation of STN, 12 weeks postoperative 15 7 03:02 30 20 
Bilateral stimulation of STN + NBM, 16-23 weeks 
postoperative (mean of 4 tests) 
23 8.5 02:29 26 20.8 
Isolated stimulation of STN + sham stimulation of NBM, 
24 weeks postoperative 
11 6 04:10 14 24 
Bilateral stimulation of STN + NBM, 24-29 weeks 
postoperative (mean of 3 tests) 
21.3 8 03:44 24.7 19.7 
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Numbers within brackets indicate standard deviations. Figure rounded to one decimal place. ADL–Activities of daily living; AVLT–Auditory 
Verbal Learning and Memory Test; BDI-II–Beck’s depression inventory; CDT–Clock drawing test; DBS–Deep brain stimulation; MMSE–Mini-
Mental State Examination; NBM–Nucleus basalis of Meynert; NR–Not reported; On/Off–On/Off phase of levodopa-related motor fluctuation; 
STN–Subthalamic nucleus; TMT-A–Trail making test part A; UPDRS–Unified Parkinson’s Disease Rating Scale; Vfl–Verbal fluency. 
AAverage of four patients as ‘case 5’ ceased medication following surgery; BAverage of four patients as MMSE was not measured in ‘case 4’ 
post-intervention. Note that for results from Kim et al., 2016, ‘case 3’ was too dysarthric for assessment at 12 months so data from 6 months 
postoperative have been used instead of 12 months. 
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Table 4: Reported outcomes in studies assessing the impact of physical activity in people with Lewy body dementia (n=16) 
Citation Measure Exercise Control 
Baseline Outcome Baseline Outcome 
Rochester et al,. 
2009  
Habitual gait speed (m/s) 0.7 (0.2) 0.9 (0.2) NA NA 
Dual task gait speed (m/s) 0.7 (0.2) 0.7 (0.2) NA NA 
Single task cadence (steps/minute) 98.7 (6.7) 104.2 (7.2) NA NA 
Ciro et al., 2013  
 
Single chair stand - COPM performance 1 5 NA NA 
Single chair stand - COPM satisfaction 1 6 NA NA 
 
Tabak et al., 2013  
 
2 Minute Walk Test - Single task (m) 100.6 129.5 NA NA 
2 Minute Walk Test - Dual task (m) 60.7 102.7 NA NA 
Functional Gait Assessment (/30) 13 23 NA NA 
MoCA (/30) 17 24 NA NA 
PDCRS (/134) 55 70 NA NA 
Color Trails Test 1 (s) 277 118 NA NA 
Color Trails Test 2 (s) 360 156 NA NA 
UPDRS I (/16) 11 1 NA NA 
UPDRS II (/52) 15 6 NA NA 
PDQ-39 (/156) 83 70 NA NA 
Dawley 2015  
 
30s sit-to-stand 4 8 NA NA 
Habitual gait speed - 7.6m walk test (m/s) 0.8 1.4 NA NA 
6 Minute Walk Test - Single task (m) 480.4 562.1 NA NA 
 32 
 
Balance - MiniBESTest (/28) 
 
21 25 NA NA 
Balance - Timed Up & Go Test (s) 
 
15.5 9.1 NA NA 
G-code: Mobility (% impairment) 67 40 NA NA 
Telenius et al., 2015  
 
30s sit-to-stand 5.5 (0.5) 8 (0.0) 5.5 (2.3) 6 (2.0) 
Habitual gait speed – 6m walk test (m/s) 
 
0.4 (0.0) 0.5 (0.2) 0.5 (0.1) 0.4 (0.1) 
Maximal gait speed – 6m walk test (m/s) 0.8 (0.3) 1.0 (0.5) 0.8 (0.1) 0.8 (0.3) 
Berg balance scale (/56) 23A 27A 35.5 (6.5) 35.5 (5.5) 
Activities of daily living –Barthel index (/20) 12 (1) 12B 11.5 (0.5) 13.5 (0.5) 
 
Figures rounded to 1dp. COPM–Canadian Occupational Performance Measure; MoCA–Montreal Cognitive Assessment; NA–Not Applicable; 
PDCRS–Parkinson’s Disease Cognitive Rating Scale; PDQ-39–Parkinson’s Disease Questionnaire-39; UPDRS–Unified Parkinson’s Disease 
Rating Scale (I–Mood & Cognition, II–Activities of Daily Living). AResult only reported for first intervention participant; BResult only reported 
for second intervention participant. 
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Table 5: Oxford Centre for Evidence-Based Medicine levels of evidence  for the efficacy of 
non-pharmacological interventions for various symptoms of Lewy body dementia  
Symptoms Non-
pharmacological 
intervention 
Highest 
level of 
evidence 
Citation for highest 
level of evidence 
Cognitive DBS 5 Freund, et al., 2009  
tDCS 3 Elder, et al., 2016  
Exercise 4 Tabak, et al., 2013  
Activities of daily living DBS 5 Loher, et al., 2002  
Exercise 4 Tabak, et al., 2013  
Neuropsychiatric Depression DBS 5 Freund, et al., 2009  
ECT 4 Takahashi, et al., 2009  
rTMS 4 Takahashi, et al., 2009  
Exercise 4 Tabak, et al., 2013  
Hallucinations ECT 4 Rasmussen, et al., 2003  
Delusions ECT 5 Fujiwara, et al., 2004  
Motor DBS 4 Kim, et al., 2016  
Exercise 4 Telenius, et al., 2014  
 
‘Motor’ refers to Parkinsonian motor symptoms such as bradykinesia and resting tremor. 
DBS–deep brain stimulation; ECT–electroconvulsive therapy; rTMS–repetitive transcranial 
magnetic stimulation; tDCS–transcranial direct current stimulation; Level of evidence 3- 
Non-randomized controlled cohort/follow-up study; Level of  evidence 4- Case-series, case-
control studies, or historically controlled studies; Level of evidence 5- Mechanism-based 
reasoning 
 
 
 
 
